ArticleNature microbiology2022
Pathogenomic analyses of Shigella isolates inform factors limiting shigellosis prevention and control across LMICs.
Article in Nature microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06523231 (Safety and Immunogenicity of a Second Generation Shigella Bioconjugate Vaccine), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Immunogenicity of a Second Generation Shigella Bioconjugate Vaccine: a Phase II Randomized, Controlled, and Blinded Study in 9-month-old Infants
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Molecular epidemiology of extended-spectrum beta-lactamases and carbapenemases-producing Shigella in Africa: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Expanded prevalence of group 4 capsule expression and its genetic requirements in a broad array ofmSphere · 2026Article
- Genomic epidemiology and antimicrobial resistance profile ofMicrobial genomics · 2026Article
- The Burden and Genomic Characterization ofmedRxiv : the preprint server for health sciences · 2026Article
- Genomes of enteric pathogen isolates from polymicrobial infections in cases of pediatric diarrhea.Microbiology resource announcements · 2026Article
- A dual functional inhibitory molecule to combat GyrA-ParC and associated mutants in fluoroquinolone-resistantFrontiers in bioinformatics · 2026Article
- Quantifying plasmid movement in drug-resistant Shigella species using phylodynamic inference.PLoS pathogens · 2025Article
- Genomic and epidemiological characteristics ofPathogens and global health · 2025Article
- Extended spectrum β-lactamase and integron genes among Shigella flexneri and Shigella sonnei isolated from children with diarrhea in shiraz, Southwest Iran.BMC pediatrics · 2025Article
- Multiple Enzymes Expressed by the Gut Microbiota Can Transform Typhaneoside and Are Associated with Improving Hyperlipidemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Characterization ofmBio · 2025Article
- Whole genome analysis ofFrontiers in veterinary science · 2025Article
- Prevalence of plasmid-mediated quinolone resistance genes and biofilm formation in different species of quinolone-resistant clinical Shigella isolates: a cross-sectional study.European journal of medical research · 2024Article
- Recent progress inFood chemistry: X · 2024Review
- Microbiological Methods Used in the Enterics for Global HealthOpen forum infectious diseases · 2024Article
- Comparative genomics of Brucella abortus and Brucella melitensis unravels the gene sharing, virulence factors and SNP diversity among the standard, vaccine and field strains.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Article
- The genomic epidemiology of shigellosis in South Africa.Nature communications · 2023Article
- Shigella Serotypes Associated With Carriage in Humans Establish Persistent Infection in Zebrafish.The Journal of infectious diseases · 2023Article
- Identification and characterization of a novel lytic peptidoglycan transglycosylase (MltC) in Shigella dysenteriae.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
Shigella spp. are the leading bacterial cause of severe childhood diarrhoea in low- and middle-income countries (LMICs), are increasingly antimicrobial resistant and have no widely available licenced vaccine. We performed genomic analyses of 1,246 systematically collected shigellae sampled from seven countries in sub-Saharan Africa and South Asia as part of the Global Enteric Multicenter Study (GEMS) between 2007 and 2011, to inform control and identify factors that could limit the effectiveness of current approaches. Through contemporaneous comparison among major subgroups, we found that S. sonnei contributes ≥6-fold more disease than other Shigella species relative to its genomic diversity, and highlight existing diversity and adaptative capacity among S. flexneri that may generate vaccine escape variants in <6 months. Furthermore, we show convergent evolution of resistance against ciprofloxacin, the current WHO-recommended antimicrobial for the treatment of shigellosis, among Shigella isolates. This demonstrates the urgent need to integrate existing genomic diversity into vaccine and treatment plans for Shigella, providing a framework for the focused application of comparative genomics to guide vaccine development, and the optimization of control and prevention strategies for other pathogens relevant to public health policy considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.